Cesar A. Perez

1.7k total citations
103 papers, 1.1k citations indexed

About

Cesar A. Perez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Cesar A. Perez has authored 103 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 29 papers in Molecular Biology. Recurrent topics in Cesar A. Perez's work include Head and Neck Cancer Studies (20 papers), Lung Cancer Treatments and Mutations (17 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Cesar A. Perez is often cited by papers focused on Head and Neck Cancer Studies (20 papers), Lung Cancer Treatments and Mutations (17 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Cesar A. Perez collaborates with scholars based in United States, United Kingdom and Spain. Cesar A. Perez's co-authors include Ian Mohr, Derek Walsh, Edgardo S. Santos, Luis E. Raez, David Khoo, Matthew Adlam, Maureen A. Morrow, Gerald Siu, Caleb McKinney and Michel Velez and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Cesar A. Perez

97 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cesar A. Perez United States	18	435	407	211	196	182	103	1.1k
Takao Kinjo Japan	18	230 0.5×	227 0.6×	273 1.3×	158 0.8×	119 0.7×	57	967
Sayuri Miyauchi United States	17	348 0.8×	358 0.9×	155 0.7×	461 2.4×	104 0.6×	37	1.0k
Mercedes Porosnicu United States	17	287 0.7×	276 0.7×	204 1.0×	201 1.0×	132 0.7×	50	1.0k
Joseph C. K. Lee Hong Kong	17	801 1.8×	678 1.7×	153 0.7×	140 0.7×	120 0.7×	35	1.7k
Anne I.J. Arens Netherlands	18	897 2.1×	552 1.4×	85 0.4×	129 0.7×	134 0.7×	49	1.6k
Nikiforos Kapranos Greece	21	342 0.8×	326 0.8×	272 1.3×	116 0.6×	145 0.8×	52	1.2k
Luis León‐Mateos Spain	17	256 0.6×	372 0.9×	121 0.6×	92 0.5×	379 2.1×	89	1.1k
Gabriella Della Torre Italy	20	518 1.2×	578 1.4×	141 0.7×	179 0.9×	291 1.6×	47	1.3k
Mohammad Reza Haghshenas Iran	16	277 0.6×	533 1.3×	282 1.3×	523 2.7×	89 0.5×	73	1.1k
Mitsuo Yoshinouchi Japan	22	906 2.1×	512 1.3×	416 2.0×	189 1.0×	115 0.6×	57	1.6k

Countries citing papers authored by Cesar A. Perez

Since Specialization

Citations

This map shows the geographic impact of Cesar A. Perez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cesar A. Perez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cesar A. Perez more than expected).

Fields of papers citing papers by Cesar A. Perez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cesar A. Perez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cesar A. Perez. The network helps show where Cesar A. Perez may publish in the future.

Co-authorship network of co-authors of Cesar A. Perez

This figure shows the co-authorship network connecting the top 25 collaborators of Cesar A. Perez. A scholar is included among the top collaborators of Cesar A. Perez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cesar A. Perez. Cesar A. Perez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tsimberidou, Apostolia M., Farshid Dayyani, David Sommerhalder, et al.. (2025). Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors. The Oncologist. 30(7).

Perez, Cesar A., et al.. (2025). Phase I dose-escalation study of the next-generation nectin-4 targeting antibody–drug conjugate CRB-701 (SYS6002) in US and UK patients with urothelial cancer and other solid tumors.. Journal of Clinical Oncology. 43(5_suppl). 807–807. 1 indexed citations

Hecht, J. Randolph, Diwakar Davar, Marwan Fakih, et al.. (2025). Phase 1/2 study of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors and in MSS CRC.. Journal of Clinical Oncology. 43(4_suppl). 206–206. 1 indexed citations

Rosenberg, Ari J., et al.. (2024). Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy. American Society of Clinical Oncology Educational Book. 44(3). e433330–e433330. 5 indexed citations

Peters, Solange, Antoine Hollebecque, Kartik Sehgal, et al.. (2024). Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).. Journal of Clinical Oncology. 42(16_suppl). 8521–8521. 3 indexed citations

Garmezy, Benjamin, Mitesh J. Borad, Cesar A. Perez, et al.. (2024). A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. Cancer Research Communications. 4(4). 1165–1173. 9 indexed citations

Cassier, Philippe A., Janice M. Mehnert, Richard D. Kim, et al.. (2024). 613MO A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) & BRAF-altered solid tumors. Annals of Oncology. 35. S491–S492. 2 indexed citations

Fayette, Jérôme, Florian Clatot, Irene Braña, et al.. (2024). Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.. Journal of Clinical Oncology. 42(16_suppl). 6014–6014. 12 indexed citations

Patnaik, Amita, Nilofer S. Azad, Mitesh J. Borad, et al.. (2024). An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).. Journal of Clinical Oncology. 42(16_suppl). TPS3160–TPS3160. 1 indexed citations

10.

Garmezy, Benjamin, Mitesh J. Borad, L-T. Chen, et al.. (2023). 130P Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations. Annals of Oncology. 34. S231–S232. 1 indexed citations

11.

Perez, Cesar A., Jason T. Henry, Nehal J. Lakhani, et al.. (2023). 660MO First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001). Annals of Oncology. 34. S464–S465. 9 indexed citations

12.

Luckett, Daniel J., Cesar A. Perez, Judy S. Wang, et al.. (2023). Abstract 921: Identification of NRG1 fusions in patients with solid tumors: analysis from a real-world community oncology network. Cancer Research. 83(7_Supplement). 921–921. 1 indexed citations

13.

Harding, James J., Cesar A. Perez, Shumei Kato, et al.. (2023). P-137 Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations. Annals of Oncology. 34. S63–S64. 1 indexed citations

14.

Perez, Cesar A., Jason T. Henry, Sunnie S. Y. Kim, et al.. (2023). 743 INCLINE-101: preliminary safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TAC-001 (TLR9 agonist conjugated to a CD22 mAb) in patients with advanced or metastatic solid tumors. SHILAP Revista de lepidopterología. A838–A838. 1 indexed citations

15.

Luckett, Daniel J., Marilyn Holt, Suzanne F. Jones, et al.. (2023). Clinical and molecular presentation of KRAS G12D-mutated pancreatic ductal adenocarcinoma in real-world settings.. Journal of Clinical Oncology. 41(4_suppl). 738–738. 1 indexed citations

16.

Ho, Alan L., Daniel W. Bowles, Caroline Even, et al.. (2021). 904P ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort. Annals of Oncology. 32. S803–S804. 6 indexed citations

17.

Ferrarotto, Renata, Lori J. Wirth, Jameel Muzaffar, et al.. (2020). 919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut). Annals of Oncology. 31. S663–S663. 17 indexed citations

18.

Perez, Cesar A., Mark J. Amsbaugh, Wederson M. Claudino, et al.. (2016). High-Dose Versus Weekly Cisplatin Definitive Chemoradiation Therapy for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology*Biology*Physics. 94(4). 895–895. 1 indexed citations

19.

Jain, Dharamvir, et al.. (2015). Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer. Drugs of today. 51(12). 689–689. 2 indexed citations

20.

Perez, Cesar A., et al.. (2011). Novel molecular targeted therapies for refractory thyroid cancer. Head & Neck. 34(5). 736–745. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact